Latest news with #AltPep
Yahoo
2 days ago
- Health
- Yahoo
AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer's Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation
Highly selective targeting in Tg AD mouse model improved short-term memory and reduced plaque burden SEATTLE, July 28, 2025--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases will today present new preclinical data at the Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada, reinforcing the promising potential of its lead compound, SOBIN-AD (Soluble Oligomer Binding INhibitor), as a treatment for early Alzheimer's disease (AD). "We are thrilled to showcase these exciting preclinical results for our SOBIN-AD therapeutic," said Valerie Daggett, Ph.D., CEO and Founder of AltPep. "Our compound is based on the discovery that toxic oligomers, early triggers for amyloid diseases such as AD, form a nonstandard protein structure called α-sheet. We have now demonstrated that SOBIN-AD not only selectively targets the α-sheet toxic oligomers but also enhances clearance of these toxic oligomers." Carolyn Tallon, Ph.D., Principal Scientist, who will present the AltPep data at AAIC, further commented, "Importantly, we showed that SOBIN-AD treatment improved short-term memory and reduced plaque burden in Tg AD mice, after 6 and 12 months of dosing, respectively. These exciting data mark a major milestone for SOBIN-AD and bring hope for early treatment of AD." Poster Presentation Details: Title: Designed peptide increases clearance of Aβ toxic oligomers and inhibits plaque formationPoster #: 104011Date / Time: Monday, July 28, 2025: 7:30 AM – 4:15 PM EDTLocation: Exhibit Hall DE The poster will also be available in the "Scientific Publications" section of the AltPep website under "Presentations" at Select preclinical data show SOBIN-AD: binds Aβ oligomers 27,000-fold stronger than protofibrils; enhances microglial phagocytosis of toxic Aβ oligomers in a dose-dependent manner; significantly improves short-term memory in 9-month old Tg2576 AD mice after 6 months of dosing, 3X/week intranasally; and significantly reduces AB plaque burden in 15-month-old AD mice after 12 months of dosing, 3X/week intranasally. Gil Block, M.D, Ph.D., and Chief Medical Officer of AltPep remarked, "These results compellingly support the promise of SOBIN-AD as a transformative early treatment option for patients with AD. This achievement is especially important as we advance our program towards the clinic." About AltPep CorporationAltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers to both detect and neutralize them throughout disease progression. AltPep's emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer's and Parkinson's diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep's goal is to change the course of these debilitating diseases that affect over a billion people around the globe. Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep's innovative approach. About SOBIN Therapeutics and SOBA DiagnosticsSOBIN therapeutics are in development for use in concert with early detection tools to target and neutralize the toxic soluble oligomers associated with amyloid diseases. SOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases. For more information, please visit and follow us on LinkedIn. View source version on Contacts Media Contact: Susan SharpeLinnden Communicationssusan@
Business Wire
2 days ago
- Health
- Business Wire
AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer's Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation
SEATTLE--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases will today present new preclinical data at the Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada, reinforcing the promising potential of its lead compound, SOBIN-AD (Soluble Oligomer Binding INhibitor), as a treatment for early Alzheimer's disease (AD). These results compellingly support the promise of SOBIN-AD as a transformative early treatment option for patients with Alzheimer's disease, said Gil Block, MD, PhD, and AltPep CMO. 'We are thrilled to showcase these exciting preclinical results for our SOBIN-AD therapeutic,' said Valerie Daggett, Ph.D., CEO and Founder of AltPep. 'Our compound is based on the discovery that toxic oligomers, early triggers for amyloid diseases such as AD, form a nonstandard protein structure called α-sheet. We have now demonstrated that SOBIN-AD not only selectively targets the α-sheet toxic oligomers but also enhances clearance of these toxic oligomers.' Carolyn Tallon, Ph.D., Principal Scientist, who will present the AltPep data at AAIC, further commented, 'Importantly, we showed that SOBIN-AD treatment improved short-term memory and reduced plaque burden in Tg AD mice, after 6 and 12 months of dosing, respectively. These exciting data mark a major milestone for SOBIN-AD and bring hope for early treatment of AD.' Poster Presentation Details: Title: Designed peptide increases clearance of Aβ toxic oligomers and inhibits plaque formation Poster #: 104011 Date / Time: Monday, July 28, 2025: 7:30 AM – 4:15 PM EDT Location: Exhibit Hall DE The poster will also be available in the 'Scientific Publications' section of the AltPep website under 'Presentations' at Select preclinical data show SOBIN-AD: binds Aβ oligomers 27,000-fold stronger than protofibrils; enhances microglial phagocytosis of toxic Aβ oligomers in a dose-dependent manner; significantly improves short-term memory in 9-month old Tg2576 AD mice after 6 months of dosing, 3X/week intranasally; and significantly reduces AB plaque burden in 15-month-old AD mice after 12 months of dosing, 3X/week intranasally. Gil Block, M.D, Ph.D., and Chief Medical Officer of AltPep remarked, 'These results compellingly support the promise of SOBIN-AD as a transformative early treatment option for patients with AD. This achievement is especially important as we advance our program towards the clinic.' About AltPep Corporation AltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers to both detect and neutralize them throughout disease progression. AltPep's emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer's and Parkinson's diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep's goal is to change the course of these debilitating diseases that affect over a billion people around the globe. Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep's innovative approach. About SOBIN Therapeutics and SOBA Diagnostics SOBIN therapeutics are in development for use in concert with early detection tools to target and neutralize the toxic soluble oligomers associated with amyloid diseases. SOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases. For more information, please visit and follow us on LinkedIn.
National Post
2 days ago
- Health
- National Post
AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer's Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation
Article content SEATTLE — AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases will today present new preclinical data at the Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada, reinforcing the promising potential of its lead compound, SOBIN-AD (Soluble Oligomer Binding INhibitor), as a treatment for early Alzheimer's disease (AD). Article content 'We are thrilled to showcase these exciting preclinical results for our SOBIN-AD therapeutic,' said Valerie Daggett, Ph.D., CEO and Founder of AltPep. 'Our compound is based on the discovery that toxic oligomers, early triggers for amyloid diseases such as AD, form a nonstandard protein structure called α-sheet. We have now demonstrated that SOBIN-AD not only selectively targets the α-sheet toxic oligomers but also enhances clearance of these toxic oligomers.' Article content Carolyn Tallon, Ph.D., Principal Scientist, who will present the AltPep data at AAIC, further commented, 'Importantly, we showed that SOBIN-AD treatment improved short-term memory and reduced plaque burden in Tg AD mice, after 6 and 12 months of dosing, respectively. These exciting data mark a major milestone for SOBIN-AD and bring hope for early treatment of AD.' Article content Article content Poster #: Article content 104011 Article content Article content Date / Time: Article content Monday, July 28, 2025: 7:30 AM – 4:15 PM EDT Article content Article content Location: Article content Exhibit Hall DE Article content The poster will also be available in the 'Scientific Publications' section of the AltPep website under 'Presentations' at Article content Select preclinical data show SOBIN-AD: Article content binds Aβ oligomers 27,000-fold stronger than protofibrils; enhances microglial phagocytosis of toxic Aβ oligomers in a dose-dependent manner; significantly improves short-term memory in 9-month old Tg2576 AD mice after 6 months of dosing, 3X/week intranasally; and significantly reduces AB plaque burden in 15-month-old AD mice after 12 months of dosing, 3X/week intranasally. Article content Gil Block, M.D, Ph.D., and Chief Medical Officer of AltPep remarked, 'These results compellingly support the promise of SOBIN-AD as a transformative early treatment option for patients with AD. This achievement is especially important as we advance our program towards the clinic.' Article content About AltPep Corporation Article content AltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers to both detect and neutralize them throughout disease progression. AltPep's emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer's and Parkinson's diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep's goal is to change the course of these debilitating diseases that affect over a billion people around the globe. Article content Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep's innovative approach. Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content Article content
